Literature DB >> 21517698

What should be the optimal levels of blood pressure: Does the J-curve phenomenon really exist?

Maciej Banach1, Marta Michalska, Sverre E Kjeldsen, Jolanta Małyszko, Dimitri P Mikhailidis, Jacek Rysz.   

Abstract

INTRODUCTION: The blood pressure (BP) J-curve debate has lasted for over 30 years and we still cannot definitively answer all the questions. However, recent studies suggest that BP should be reduced carefully in patients with hypertension and coronary artery disease. BP should not fall below 110 - 115/70 - 75 mmHg, because this may be associated with more cardiovascular events. AREAS COVERED: A retrospective analysis of the INVEST Trial and the results of the BP arm of the ACCORD Trial shows that care is needed in patients with hypertension and diabetes. Although the ACCORD BP Trial suggests important benefits connected with the significant reduction of stroke in patients being treated intensively, it also shows the lack of advantage of such therapy on each main and other additional endpoints. The ACCORD Trial also confirmed the increased risk of adverse events that might appear when intensive treatment was used in this group of patients. EXPERT OPINION: Most available studies were observational and randomized trials (BBB, HOT, ACCORD BP), do not have or have lost their statistical power and were inconclusive. Further studies are therefore needed to provide definitive conclusions on the subject. In the meantime, it seems that in high-risk patients with hypertension, it is necessary to carefully select those who might suffer adverse events and those who may benefit from intensive BP lowering.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21517698     DOI: 10.1517/14656566.2011.579106

Source DB:  PubMed          Journal:  Expert Opin Pharmacother        ISSN: 1465-6566            Impact factor:   3.889


  16 in total

1.  Association of systolic blood pressure levels with cardiovascular events and all-cause mortality among older adults taking antihypertensive medication.

Authors:  Maciej Banach; Samantha Bromfield; George Howard; Virginia J Howard; Alberto Zanchetti; Wilbert S Aronow; Ali Ahmed; Monika M Safford; Paul Muntner
Journal:  Int J Cardiol       Date:  2014-07-22       Impact factor: 4.164

Review 2.  Hypertension-related stroke prevention in the elderly.

Authors:  Wilbert S Aronow
Journal:  Curr Hypertens Rep       Date:  2013-12       Impact factor: 5.369

Review 3.  Blood pressure j-curve: current concepts.

Authors:  Maciej Banach; Wilbert S Aronow
Journal:  Curr Hypertens Rep       Date:  2012-12       Impact factor: 5.369

4.  Current perspectives on treatment of hypertensive patients with chronic obstructive pulmonary disease.

Authors:  Dipak Chandy; Wilbert S Aronow; Maciej Banach
Journal:  Integr Blood Press Control       Date:  2013-07-09

5.  Lipids, blood pressure, kidney - what was new in 2011?

Authors:  Marcin Barylski; Jolanta Małyszko; Jacek Rysz; Michał Myśliwiec; Maciej Banach
Journal:  Arch Med Sci       Date:  2011-12-30       Impact factor: 3.318

6.  Brazilian Society of Cardiology Guidelines on Unstable Angina and Acute Myocardial Infarction without ST-Segment Elevation - 2021.

Authors:  José Carlos Nicolau; Gilson Soares Feitosa Filho; João Luiz Petriz; Remo Holanda de Mendonça Furtado; Dalton Bertolim Précoma; Walmor Lemke; Renato Delascio Lopes; Ari Timerman; José A Marin Neto; Luiz Bezerra Neto; Bruno Ferraz de Oliveira Gomes; Eduardo Cavalcanti Lapa Santos; Leopoldo Soares Piegas; Alexandre de Matos Soeiro; Alexandre Jorge de Andrade Negri; Andre Franci; Brivaldo Markman Filho; Bruno Mendonça Baccaro; Carlos Eduardo Lucena Montenegro; Carlos Eduardo Rochitte; Carlos José Dornas Gonçalves Barbosa; Cláudio Marcelo Bittencourt das Virgens; Edson Stefanini; Euler Roberto Fernandes Manenti; Felipe Gallego Lima; Francisco das Chagas Monteiro Júnior; Harry Correa Filho; Henrique Patrus Mundim Pena; Ibraim Masciarelli Francisco Pinto; João Luiz de Alencar Araripe Falcão; Joberto Pinheiro Sena; José Maria Peixoto; Juliana Ascenção de Souza; Leonardo Sara da Silva; Lilia Nigro Maia; Louis Nakayama Ohe; Luciano Moreira Baracioli; Luís Alberto de Oliveira Dallan; Luis Augusto Palma Dallan; Luiz Alberto Piva E Mattos; Luiz Carlos Bodanese; Luiz Eduardo Fonteles Ritt; Manoel Fernandes Canesin; Marcelo Bueno da Silva Rivas; Marcelo Franken; Marcos José Gomes Magalhães; Múcio Tavares de Oliveira Júnior; Nivaldo Menezes Filgueiras Filho; Oscar Pereira Dutra; Otávio Rizzi Coelho; Paulo Ernesto Leães; Paulo Roberto Ferreira Rossi; Paulo Rogério Soares; Pedro Alves Lemos Neto; Pedro Silvio Farsky; Rafael Rebêlo C Cavalcanti; Renato Jorge Alves; Renato Abdala Karam Kalil; Roberto Esporcatte; Roberto Luiz Marino; Roberto Rocha Corrêa Veiga Giraldez; Romeu Sérgio Meneghelo; Ronaldo de Souza Leão Lima; Rui Fernando Ramos; Sandra Nivea Dos Reis Saraiva Falcão; Talia Falcão Dalçóquio; Viviana de Mello Guzzo Lemke; William Azem Chalela; Wilson Mathias Júnior
Journal:  Arq Bras Cardiol       Date:  2021-07       Impact factor: 2.667

Review 7.  Blood pressure levels and stroke: J-curve phenomenon?

Authors:  Jolanta Malyszko; Paul Muntner; Jacek Rysz; Maciej Banach
Journal:  Curr Hypertens Rep       Date:  2013-12       Impact factor: 5.369

8.  Aliskiren - an alternative to angiotensin-converting enzyme inhibitors or angiotensin receptor blockers in the therapy of arterial hypertension.

Authors:  Iwona Zaporowska-Stachowiak; Karolina Hoffmann; Wiesław Bryl; Andrzej Minczykowski
Journal:  Arch Med Sci       Date:  2013-04-30       Impact factor: 3.318

9.  What should the optimal blood pressure goal be in patients with diabetes mellitus or chronic kidney disease?

Authors:  Wilbert S Aronow
Journal:  Arch Med Sci       Date:  2012-07-04       Impact factor: 3.318

10.  Blood pressure at hospital admission and outcome after primary intracerebral hemorrhage.

Authors:  Erwin Chiquete; Ana Ochoa-Guzmán; Angel Vargas-Sánchez; Jorge Navarro-Bonnet; Miquel A Andrade-Ramos; Patricia Gutiérrez-Plascencia; José L Ruiz-Sandoval
Journal:  Arch Med Sci       Date:  2013-02-21       Impact factor: 3.318

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.